Cardio Diagnostics Enters Partnerships With 15 New U.S. Provider Organizations, Expanding Adoption Of Its AI-driven Blood Tests, Epi+Gen CHD And PrecisionCHD Which Aim To Improve Prevention, Detection, And Management Of Coronary Heart Disease Across Diverse Clinical Settings
Benzinga Newsdesk 1 year ago
BiotechNewsContractsGeneral
Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care PracticesCardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven Precision Cardiovascular
Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings.